Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: phoenix_rising who wrote (1562)	11/18/2015 3:12:58 PM
From: Mirror Image	Read Replies (2) \| Respond to of 2026

What can I say Phoenix. I have been an Apricus ( Nexmed then ) since 2009. Back when Vitaros was a promise. I know where you are coming from. I have thought about throwing in the towel at various points. What keeps me from doing so is that fact that we have a selling product. Which is barely in ramp up mode, selling in only 7 countries so far - from a pool that includes the Entire Planet. Royalties should increase over time substantially - more and more so with each new launch. We can look at the overall picture. We are currently trading in the $1.20 range. We know that we are going to need financing. Short Interest stands at almost a 52 week high. But even so - it's only 6% of the shares Outstanding. Institutional Ownership stands at about 32%. Growing slowly but steadily quarter over quarter ( they also know that Apricus will need financing shortly ). Question for you. If all things are even and EVERYBODY knows that Apricus will need financing ( which we all do ). Why is the volume so low? Why isn't short interest taking advantage and applying more pressure by shorting more? My answer to that is the fact that there is only $1.20 to be made to the downside ( and you need a killer blow to get it there - not even RPRX is at that point and look what has transpired over there ). The upside has way more reward. $1.20 to the upside takes it only to $2.40 ( and it's easier to take it to $2.40 than it is to 0 ). We have remember that we have value in Vitaros ( and I only bring Vitaros up because it's the drug that is generating revenue at the moment ). As long as the units sold per quarter keep increasing - whether by more countries selling or growth in existing markets. It will create more value. I know that it's frustrating to have the months/years go by and not have much to show for as a Apricus Investor. But I think we eventually will. Whether it's because of Fispemifene or because "they" decide to manipulate the stock in the other direction in order to make money. Or Vitaros finally launches in many more countries and we reach a steady 1 million units sold per month. Here is to having the patience to see this through ( and when we do decide to sell - we make a nice profit ).